CVRx, Inc.

NasdaqGS:CVRX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🏥 Hospitals & Clinics

🩺 Medical Instruments

💻 Telehealth

Location

United States

Market Cap

USD 152.79 M

Share Price

USD 5.86

Avg Daily Volume

421,031

Change (1 day)

-1.18%

Change (1 year)

-41.92%

Change (YTD)

-53.75%

CVRx, Inc. Price to Sales Ratio (P/S) on June 13, 2025: 2.89

CVRx, Inc. Price to Sales Ratio (P/S) is 2.89 on June 13, 2025, a -46.77% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

CVRx, Inc. 52-week low Price to Sales Ratio (P/S) is 10.10 on June 13, 2025, which is 249.44% above the current Price to Sales Ratio (P/S).
CVRx, Inc. 52-week low Price to Sales Ratio (P/S) is 2.34 on June 13, 2025, which is -18.94% below the current Price to Sales Ratio (P/S).
CVRx, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 5.45.

Daily

From:

To:

Zoom:

Key data

Date	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield

NasdaqGS: CVRX

CVRx, Inc.

CEO	Mr. Kevin Hykes
IPO Date	June 30, 2021
Location	United States
Headquarters	9201 West Broadway Avenue
Employees	206
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🏥 Hospitals & Clinics 🩺 Medical Instruments 💻 Telehealth

Description

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.